Lenvima sales and marketing update

In a final benefit assessment, Germany’s Federal Joint Committee (G-BA) concluded that Kisplyx lenvatinib plus Afinitor everolimus provides additional benefit in treating advanced renal cell carcinoma (RCC) compared to everolimus alone. G-BA based the assessment on data from the Phase II Study 205 trial, in which Kisplyx plus everolimus met the primary endpoint of improving median progression-free survival (PFS) vs. everolimus alone (14.6 vs. 5.5 months, p=0.0005) in patients with unresectable, advanced or metastatic RCC following one prior VEGF-targeted treatment (see BioCentury, June 8, 2015)...